このエントリーをはてなブックマークに追加


ID 62215
FullText URL
Author
Adachi, Takuya Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Takeuchi, Yasuto Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Takaki, Akinobu Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
Oyama, Atsushi Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Wada, Nozomu Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Onishi, Hideki Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Shiraha, Hidenori Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
Okada, Hiroyuki Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
Abstract
Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2. Given that liver cirrhosis patients exhibit hyponatremia due to their pseudo-aldosteronism and usage of natriuretic agents, a sodium maintaining agent, such as tolvaptan, is physiologically preferable. However, large scale studies indicating the patients for whom this would be effective and describing management under its use have been insufficient. The appropriate management of cirrhosis patients treated with tolvaptan should be investigated. In the present review, we collected articles investigating the effectiveness of tolvaptan and factors associated with survival and summarized their management reports. Earlier administration of tolvaptan before increasing the doses of natriuretic agents is recommended because this may preserve effective arterial blood volume.
Keywords
tolvaptan
liver cirrhosis
ascites
Published Date
2021-05-25
Publication Title
International Journal of Molecular Sciences
Volume
volume22
Issue
issue11
Publisher
MDPI
Start Page
5582
ISSN
1422-0067
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2021 by the authors.
File Version
publisher
PubMed ID
NAID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.3390/ijms22115582
License
https://creativecommons.org/licenses/by/4.0/